MX2009012054A - Metodos de tratamiento que usan formulaciones intravenosas que comprenden temozolomida. - Google Patents

Metodos de tratamiento que usan formulaciones intravenosas que comprenden temozolomida.

Info

Publication number
MX2009012054A
MX2009012054A MX2009012054A MX2009012054A MX2009012054A MX 2009012054 A MX2009012054 A MX 2009012054A MX 2009012054 A MX2009012054 A MX 2009012054A MX 2009012054 A MX2009012054 A MX 2009012054A MX 2009012054 A MX2009012054 A MX 2009012054A
Authority
MX
Mexico
Prior art keywords
methods
temozolomide
treatment
drug products
intravenous formulations
Prior art date
Application number
MX2009012054A
Other languages
English (en)
Inventor
Malaz Abutarif
Paul Statkevich
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009012054A publication Critical patent/MX2009012054A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se refiere a métodos y productos de fármaco para tratar trastornos proliferativos usando formulaciones intravenosas que comprenden temozolomida durante un tiempo de infusión específico; estos métodos y productos de fármaco son particularmente muy adecuados para pacientes que no pueden digerir formulaciones orales; estos métodos y productos de fármaco también proporcionan conveniencia agregada a pacientes que ya están recibiendo otros tratamientos terapéuticos.
MX2009012054A 2007-05-08 2008-05-07 Metodos de tratamiento que usan formulaciones intravenosas que comprenden temozolomida. MX2009012054A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91662207P 2007-05-08 2007-05-08
US1374307P 2007-12-14 2007-12-14
PCT/US2008/005875 WO2008140724A1 (en) 2007-05-08 2008-05-07 Methods of treatment using intravenous formulations comprising temozolomide

Publications (1)

Publication Number Publication Date
MX2009012054A true MX2009012054A (es) 2009-11-19

Family

ID=39643416

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012054A MX2009012054A (es) 2007-05-08 2008-05-07 Metodos de tratamiento que usan formulaciones intravenosas que comprenden temozolomida.

Country Status (13)

Country Link
US (1) US20100210700A1 (es)
EP (2) EP2409700A1 (es)
JP (1) JP2010526809A (es)
CN (1) CN101678002A (es)
AU (1) AU2008251921A1 (es)
BR (1) BRPI0823416A2 (es)
CA (1) CA2686848A1 (es)
CL (1) CL2008001332A1 (es)
MX (1) MX2009012054A (es)
NZ (1) NZ580982A (es)
TW (1) TW200845962A (es)
WO (1) WO2008140724A1 (es)
ZA (1) ZA200907834B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036676A2 (en) 2009-09-23 2011-03-31 Ashwini Nangia Stable cocrystals of temozolomide
WO2011077458A1 (en) * 2009-12-23 2011-06-30 Sahaj Life Sciences Pvt. Ltd. Formulations of temozolomide for parenteral administration
WO2011106577A2 (en) * 2010-02-26 2011-09-01 Niiki Pharma Inc. Method for treating brain cancer
CN101869551B (zh) * 2010-06-28 2012-04-18 江苏奥赛康药业股份有限公司 一种替莫唑胺冻干制剂
CN102949350A (zh) * 2011-08-16 2013-03-06 上海汇伦生命科技有限公司 一种替莫唑胺的冻干制剂及其制备方法
US8974811B2 (en) 2013-03-14 2015-03-10 Hikma Pharmaceuticals Stabilized pharmaceutical formulations comprising antineoplastic compounds
CN103147830B (zh) * 2013-03-26 2016-09-28 凯龙高科技股份有限公司 一种scr尾气后处理系统故障诊断仪

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
US5268368A (en) * 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
US5407804A (en) 1992-05-22 1995-04-18 Applied Genetics Inc. Assays for O6 -methylguanine-DNA methyltransferase
GB9224888D0 (en) 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5942247A (en) 1996-07-31 1999-08-24 Schering Corporation Method for treating pediatric high grade astrocytoma including brain stem glioma
US5824346A (en) 1996-08-22 1998-10-20 Schering Corporation Combination therapy for advanced cancer
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
ATE355841T1 (de) 1997-12-13 2007-03-15 Bristol Myers Squibb Co Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6346524B1 (en) 1999-03-30 2002-02-12 Schering Corporation Cancer treatment with temozolomide
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
ES2302699T3 (es) 1999-08-27 2008-08-01 Novartis Vaccines And Diagnostics, Inc. Oligonucleotidos quimericos antisentido y formulaciones de transfeccion celular de los mismos.
DK1218494T3 (da) 1999-09-22 2005-08-08 Canbas Co Ltd Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler
BR0017043A (pt) * 1999-12-24 2003-01-07 Bayer Ag Imidazo[1,3,5]triazinonas e sua aplicação
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
GB0017508D0 (en) 2000-07-17 2000-08-30 Novartis Ag Antimicrobials
DE10034801A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Amidoalkyl-uracile und ihre Verwendung
CN100457753C (zh) 2000-07-26 2009-02-04 布里斯托尔-迈尔斯斯奎布公司 依赖细胞周期蛋白的激酶的n－[5－[[[5－烷基－2－唑基]甲基]硫代]－2－噻唑基]甲酰胺抑制剂
CA2422890C (en) 2000-09-29 2013-04-23 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
AU2002214320A1 (en) * 2000-11-20 2002-05-27 Takeda Chemical Industries Ltd. Imidazole derivatives, process for their preparation and their use
US6703400B2 (en) 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
DK1478339T3 (da) * 2002-02-22 2008-08-25 Schering Corp Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200536536A (en) 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors
US20060100188A1 (en) * 2004-11-09 2006-05-11 Chen Zong Treatment methods
EP1838307A1 (en) * 2004-12-02 2007-10-03 Schering Corporation Methods of using temozolomide formulation intrathecally in the treatment of cancers
AR055206A1 (es) 2005-10-06 2007-08-08 Schering Corp Pirazolo[1, 5 - a]pirimidinas como inhibidoras de proteina quinasa, composiciones farmaceuticas y combinaciones con agentes citostaticos que las comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
US7645762B2 (en) 2005-10-06 2010-01-12 Schering Corporation Substituted pyrazolo[1,5-a] pyrimidines as protein kinase inhibitors
WO2007044441A2 (en) 2005-10-06 2007-04-19 Schering Corporation Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
EP1931676B1 (en) 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors

Also Published As

Publication number Publication date
CA2686848A1 (en) 2008-11-20
US20100210700A1 (en) 2010-08-19
AU2008251921A2 (en) 2010-01-07
TW200845962A (en) 2008-12-01
CL2008001332A1 (es) 2009-01-02
EP2157972A1 (en) 2010-03-03
NZ580982A (en) 2012-05-25
AU2008251921A1 (en) 2008-11-20
BRPI0823416A2 (pt) 2015-06-16
WO2008140724A1 (en) 2008-11-20
ZA200907834B (en) 2011-04-28
CN101678002A (zh) 2010-03-24
JP2010526809A (ja) 2010-08-05
EP2409700A1 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
MX2009012054A (es) Metodos de tratamiento que usan formulaciones intravenosas que comprenden temozolomida.
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
NZ707377A (en) Combination therapy methods for treating proliferative diseases
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2011009020A3 (en) Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
IL196425A (en) Dosage unit for oral administration containing ibuprofen and pamotidine
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
WO2008067991A3 (en) Skin-friendly drug complexes for transdermal administration
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
MX2021002083A (es) Composiciones farmaceuticas que contienen insulina.
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
EP2424536A4 (en) NEW PHOTOSENSIBILIZER FORMULATIONS FOR ORAL ADMINISTRATION
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
WO2012125871A3 (en) Aconitine compounds, compositions, uses, and preparation thereof
WO2008079818A3 (en) Intravenous administration of water soluble analgesic formulations

Legal Events

Date Code Title Description
HH Correction or change in general
HC Change of company name or juridical status

Owner name: LUBRIZOL SPECIALTY PRODUCTS, INC.

FA Abandonment or withdrawal